FKB238 (bevacizumab)
FKB238-002
Phase 3 small_molecule completed
Quick answer
FKB238 (bevacizumab) for Carcinoma, Non-Small-Cell Lung is a Phase 3 program (small_molecule) at Centus Biotherapeutics Europe Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Centus Biotherapeutics Europe Limited
- Indication
- Carcinoma, Non-Small-Cell Lung
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed